Identification
- Generic Name
- L-tartaric acid
Commonly known or available as Tartaric acid - DrugBank Accession Number
- DB09459
- Background
Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics, and is a dihydroxyl derivative of succinic acid.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for L-tartaric acid (DB09459)
- Weight
- Average: 150.0868
Monoisotopic: 150.016437924 - Chemical Formula
- C4H6O6
- Synonyms
- (+)-(R,R)-tartaric acid
- (+)-L-tartaric acid
- (+)-Tartaric acid
- (+)-Weinsäure
- (2R,3R)-2,3-Dihydroxybernsteinsäure
- (2R,3R)-2,3-dihydroxysuccinic acid
- (2R,3R)-Tartaric acid
- (R,R)-(+)-tartaric acid
- (R,R)-Tartaric acid
- ácido tartárico
- L-threaric acid
- Rechtsweinsäure
- Tartaric acid
- Weinsteinsäure
- External IDs
- E 334
- E-334
- FEMA NO. 3044
- INS NO.334
- INS-334
- NSC-62778
Pharmacology
- Indication
Tartaric Acid is primarily indicated in conditions like Antiscorbutic, Antiseptic.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Acid indigestion ••• ••• Symptomatic treatment of Heartburn ••• ••• Used in combination to prevent Kidney stones Combination Product in combination with: Sodium citrate (DB09154), Sodium bicarbonate (DB01390), Citric acid (DB04272) ••• ••• •••••••• ••••••••••••• •••••••• ••• •••••••• Used in combination for symptomatic treatment of Pain Combination Product in combination with: Sodium citrate (DB09154), Citric acid (DB04272), Sodium bicarbonate (DB01390) ••• ••• •••••••• ••••••••••••• •••••••• ••• •••••••• Symptomatic treatment of Upset stomach ••• ••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Tartaric acid is used to generate carbon dioxide through interaction with sodium bicarbonate following oral administration. Carbon dioxide extends the stomach and provides a negative contrast medium during double contrast radiography. In high doses, this agent acts as a muscle toxin by inhibiting the production of malic acid, which could cause paralysis and maybe death.
- Mechanism of action
- Not Available
- Absorption
Oral or parenteral doses of monosodium 14C-L(+)-tartrate (400 mg/kg) are rapidly excreted by rats and a proportion completely metabolized to CO2. The oral dose was well-absorbed.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Most tartarate that is consumed by humans is metabolized by bacteria in the gastrointestinal tract , primarily in the large instestine.
- Route of elimination
Only about 15-20% of consumed tartaric acid is secreted in the urine unchanged.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Routes of Entry: Inhalation. Ingestion.
Toxicity to Animals: Lowest Published Lethal Dose: LDL [Rat - Route: oral; Dose: 7500 mg/kg LDL Rabbit - Route: Oral; Dose: 5000 mg/kg LDL [Dog] - Rout: Oral; Dose: 5000 mg/kg Lethal Dose/Conc 50% kill: LD50 [Mouse] - Route: Intravenous; Dose: 485 mg/kg3
Other Toxic Effects on Humans: Acute Potential Health Effects: Skin: Causes skin irritation Eyes: Causes eye irritation Inhalation: Causes respiratory tract irritation Ingestion: Causes gastrointestinal tract irritation with nausea, vomiting and diarrhea. May affect kidneys (kidney damage), blood, and behavior (convulsions, somnolence), and respiration. Chronic Potential Health Effects: Ingestion: Repeated or prolonged ingestion may cause lesions of the mouth, gastric ulcers, gastrointestinal hyperacidity, and symptoms similar to those of metal fume fever - flu-like condition with fever, chills, sweats, nausea, vomiting, muscle aches, pains, and weakness. Skin: Repeated or prolonged skin contact may cause skin ulcerations or lesions.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmphetamine The excretion of Amphetamine can be decreased when combined with L-tartaric acid. Benzphetamine The excretion of Benzphetamine can be decreased when combined with L-tartaric acid. Demeclocycline The therapeutic efficacy of Demeclocycline can be decreased when used in combination with L-tartaric acid. Dextroamphetamine The excretion of Dextroamphetamine can be decreased when combined with L-tartaric acid. Diethylpropion The excretion of Diethylpropion can be decreased when combined with L-tartaric acid. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AVORAL EFFERVESCENT GRANULES L-tartaric acid (0.89 g) + Citric acid (0.72 g) + Sodium bicarbonate (1.76 g) + Sodium citrate (0.63 g) Granule, for solution Oral XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD 2020-09-08 Not applicable Malaysia 
Avosoda Effervescent Granules L-tartaric acid (0.89 g) + Citric acid (0.72 g) + Sodium bicarbonate (1.76 g) + Sodium citrate (0.63 g) Granule, for solution Oral Abio Marketing Sdn Bhd 2020-09-08 Not applicable Malaysia Baros Effervescent Granules L-tartaric acid (420 mg / g) + Sodium bicarbonate (460 mg / g) Granule, effervescent Oral Tyco Healthcare 1988-12-31 2010-01-07 Canada 
BAROS EFFERVESCENT GRANULES L-tartaric acid (420 mg/g) + Sodium bicarbonate (460 mg/g) Granule Oral EISAI (SINGAPORE) PTE. LTD. 1991-05-08 Not applicable Singapore 
Bicaruvas L-tartaric acid (2 g/944mL) + Calcium carbonate (1 g/944mL) + Citric acid monohydrate (15 g/944mL) + Sodium bicarbonate (19 g/944mL) Powder, for solution Oral Prosana Distribuciones, S.A. De C.V. 2013-04-23 Not applicable US 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Sugar acids and derivatives
- Alternative Parents
- Short-chain hydroxy acids and derivatives / Beta hydroxy acids and derivatives / Monosaccharides / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / 1,2-diols / Carboxylic acids / Organic oxides show 2 more
- Substituents
- 1,2-diol / Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dicarboxylic acid or derivatives / Fatty acid show 7 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- tartaric acid (CHEBI:15671)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W4888I119H
- CAS number
- 87-69-4
- InChI Key
- FEWJPZIEWOKRBE-JCYAYHJZSA-N
- InChI
- InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m1/s1
- IUPAC Name
- (2R,3R)-2,3-dihydroxybutanedioic acid
- SMILES
- O[C@H]([C@@H](O)C(O)=O)C(O)=O
References
- General References
- External Links
- Human Metabolome Database
- HMDB0000956
- PubChem Compound
- 444305
- PubChem Substance
- 347827854
- ChemSpider
- 392277
- 37578
- ChEBI
- 15671
- ChEMBL
- CHEMBL1236315
- ZINC
- ZINC000000895301
- PDBe Ligand
- TLA
- Wikipedia
- Tartaric_acid
- PDB Entries
- 1alu / 1d5r / 1d6j / 1ei6 / 1eks / 1fs5 / 1gu1 / 1h3d / 1j2z / 1k2y … show 548 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Healthy Volunteers (HV) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule Oral 460 mg/g Powder, for solution Oral Granule, effervescent Oral Granule Oral Powder Oral Solution Oral Tablet Oral Granule, effervescent Oral 0.72 g Granule, for solution Oral Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 161.0 mg/mL ALOGPS logP -1.3 ALOGPS logP -1.8 Chemaxon logS 0.03 ALOGPS pKa (Strongest Acidic) 2.72 Chemaxon pKa (Strongest Basic) -4.3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 115.06 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 26.21 m3·mol-1 Chemaxon Polarizability 11.33 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 126.8990803 predictedDarkChem Lite v0.1.0 [M-H]- 126.7059803 predictedDarkChem Lite v0.1.0 [M-H]- 128.7061803 predictedDarkChem Lite v0.1.0 [M-H]- 122.42015 predictedDeepCCS 1.0 (2019) [M+H]+ 129.6269803 predictedDarkChem Lite v0.1.0 [M+H]+ 130.1240803 predictedDarkChem Lite v0.1.0 [M+H]+ 130.7381803 predictedDarkChem Lite v0.1.0 [M+H]+ 125.09714 predictedDeepCCS 1.0 (2019) [M+Na]+ 126.5146803 predictedDarkChem Lite v0.1.0 [M+Na]+ 126.6384803 predictedDarkChem Lite v0.1.0 [M+Na]+ 128.0462803 predictedDarkChem Lite v0.1.0 [M+Na]+ 133.79588 predictedDeepCCS 1.0 (2019)
Drug created at November 30, 2015 19:10 / Updated at March 27, 2024 05:12